Virtual Poster Session: Practical Application of Key Data Presented During the 2016 Oncology Annual Meeting in Chicago - priME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session: Practical Application of Key Data Presented During the 2016 Oncology Annual Meeting in Chicago

Not a member of My prIME? Join now for instant access.

Virtual Poster Session: Practical Application of Key Data Presented During the 2016 Oncology Annual Meeting in Chicago

View Activity

Activity Overview

View CME-certified abstract presentations and downloadable slides covering the most up-to-date clinical trial data from the 2016 Oncology Annual Meeting in Chicago.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 6.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

  • Head and neck cancer: 1
  • Metastatic colorectal cancer: 1.25
  • Multiple myeloma: 1
  • Non-small cell lung cancer: 0.75
  • Sarcoma: 0.5
  • Skin cancer: 2

Provider

This activity is provided by prIME Oncology.

Head and Neck Cancer

Joshua Bauml, MD

Abstract #6011: Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC)

Presented by:: Joshua Bauml, MD

Laura Q.M. Chow, MD

Abstract #6010: Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Presented by:: Laura Q.M. Chow, MD

Robert Ferris, MD, PhD, FACS

Abstract #6009: Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141

Presented by:: Robert Ferris, MD, PhD, FACS

Denis Soulières, MD

Abstract #6008: BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Presented by:: Denis Soulières, MD

Metastatic Colorectal Cancer

Alan Venook, MD

Abstract #3504: Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance)

Presented by:: Alan Venook, MD

Marc Peeters, MD, PhD

Abstract #3538: Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT

Presented by:: Marc Peeters, MD, PhD

Eric Van Cutsem, MD, PhD

Abstract #3524: Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial

Presented by:: Eric Van Cutsem, MD, PhD

Michael J. Overman, MD

Abstract #3501: Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results

Presented by:: Michael J. Overman, MD

Neil H. Segal, MD, PhD

Abstract #3539: Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients

Presented by:: Neil H. Segal, MD, PhD

Johanna Bendell, MD

Abstract #3502: Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)

Presented by:: Johanna Bendell, MD

Multiple Myeloma

Philippe Moreau, MD

Abstract #8045: Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391)

Presented by:: Philippe Moreau, MD

María-Victoria Mateos, MD, PhD

Abstract #8010: Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis

Presented by:: María-Victoria Mateos, MD, PhD

María-Victoria Mateos, MD, PhD

Abstract #LBA4: Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study

Presented by:: María-Victoria Mateos, MD, PhD

Paul Richardson, MD

Abstract #8018: Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study

Presented by:: Paul Richardson, MD

Philippe Moreau, MD

Abstract #8011: Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Presented by:: Philippe Moreau, MD

Sagar Lonial, MD

Abstract #8037: ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)—Identifying responders by subset analysis

Presented by:: Sagar Lonial, MD

NSCLC

Edward Garon, MD

Abstract #9024: Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010

Presented by:: Edward Garon, MD

Rathi Pillai, MD

Abstract #9035: Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC)

Presented by:: Rathi Pillai, MD

James C-H Yang, MD, PhD

Abstract #9002: Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study

Presented by:: James C-H Yang, MD, PhD

Matthew Hellmann, MD

Abstract #3001: CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

Presented by:: Matthew Hellmann, MD

Sarcoma

Nicolas Penel, MD

Abstract #11003: Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial

Presented by:: Nicolas Penel, MD

Hussein Tawbi, MD, PhD

Abstract #11006: Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study

Presented by:: Hussein Tawbi, MD, PhD

Skin Cancer

Georgina Long, MBBS, PhD

Abstract #9568: Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB‑IV melanoma

Presented by:: Georgina Long, MBBS, PhD

Jacob Schachter, MD

Abstract #9504: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006

Presented by:: Jacob Schachter, MD

Caroline Robert, MD, PhD

Abstract #9503: Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Presented by:: Caroline Robert, MD, PhD

Antoni Ribas, MD, PhD

Abstract #3014: Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study

Presented by:: Antoni Ribas, MD, PhD

Reinhard Dummer, MD

Abstract #9500: Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma

Presented by:: Reinhard Dummer, MD

Keith Flaherty, MD

Abstract #9502: Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma

Presented by:: Keith Flaherty, MD

Howard Kaufman, MD, FACS

Abstract #9508: Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial

Presented by:: Howard Kaufman, MD, FACS

Jeffrey S. Weber, MD, PhD

Abstract #9517: Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

Presented by:: Jeffrey S. Weber, MD, PhD

Head and Neck Cancer

Joshua Bauml, MD

Abstract #6011: Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC)

Presented by:: Joshua Bauml, MD

Laura Q.M. Chow, MD

Abstract #6010: Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Presented by:: Laura Q.M. Chow, MD

Robert Ferris, MD, PhD, FACS

Abstract #6009: Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141

Presented by:: Robert Ferris, MD, PhD, FACS

Denis Soulières, MD

Abstract #6008: BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Presented by:: Denis Soulières, MD

Metastatic Colorectal Cancer

Alan Venook, MD

Abstract #3504: Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance)

Presented by:: Alan Venook, MD

Marc Peeters, MD, PhD

Abstract #3538: Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT

Presented by:: Marc Peeters, MD, PhD

Eric Van Cutsem, MD, PhD

Abstract #3524: Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial

Presented by:: Eric Van Cutsem, MD, PhD

Michael J. Overman, MD

Abstract #3501: Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results

Presented by:: Michael J. Overman, MD

Neil H. Segal, MD, PhD

Abstract #3539: Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients

Presented by:: Neil H. Segal, MD, PhD

Johanna Bendell, MD

Abstract #3502: Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)

Presented by:: Johanna Bendell, MD

Multiple Myeloma

Philippe Moreau, MD

Abstract #8045: Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391)

Presented by:: Philippe Moreau, MD

María-Victoria Mateos, MD, PhD

Abstract #8010: Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis

Presented by:: María-Victoria Mateos, MD, PhD

María-Victoria Mateos, MD, PhD

Abstract #LBA4: Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study

Presented by:: María-Victoria Mateos, MD, PhD

Paul Richardson, MD

Abstract #8018: Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study

Presented by:: Paul Richardson, MD

Philippe Moreau, MD

Abstract #8011: Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Presented by:: Philippe Moreau, MD

Sagar Lonial, MD

Abstract #8037: ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)—Identifying responders by subset analysis

Presented by:: Sagar Lonial, MD

NSCLC

Edward Garon, MD

Abstract #9024: Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010

Presented by:: Edward Garon, MD

Rathi Pillai, MD

Abstract #9035: Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC)

Presented by:: Rathi Pillai, MD

James C-H Yang, MD, PhD

Abstract #9002: Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study

Presented by:: James C-H Yang, MD, PhD

Matthew Hellmann, MD

Abstract #3001: CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

Presented by:: Matthew Hellmann, MD

Sarcoma

Nicolas Penel, MD

Abstract #11003: Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial

Presented by:: Nicolas Penel, MD

Hussein Tawbi, MD, PhD

Abstract #11006: Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study

Presented by:: Hussein Tawbi, MD, PhD

Skin Cancer

Georgina Long, MBBS, PhD

Abstract #9568: Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB‑IV melanoma

Presented by:: Georgina Long, MBBS, PhD

Jacob Schachter, MD

Abstract #9504: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006

Presented by:: Jacob Schachter, MD

Caroline Robert, MD, PhD

Abstract #9503: Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Presented by:: Caroline Robert, MD, PhD

Antoni Ribas, MD, PhD

Abstract #3014: Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study

Presented by:: Antoni Ribas, MD, PhD

Reinhard Dummer, MD

Abstract #9500: Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma

Presented by:: Reinhard Dummer, MD

Keith Flaherty, MD

Abstract #9502: Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma

Presented by:: Keith Flaherty, MD

Howard Kaufman, MD, FACS

Abstract #9508: Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial

Presented by:: Howard Kaufman, MD, FACS

Jeffrey S. Weber, MD, PhD

Abstract #9517: Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

Presented by:: Jeffrey S. Weber, MD, PhD

Support

This educational activity is supported by grants from Amgen, Bayer HealthCare Pharmaceuticals, and Merck and Co, Inc.